GB0524103D0 - Healing - Google Patents

Healing

Info

Publication number
GB0524103D0
GB0524103D0 GBGB0524103.9A GB0524103A GB0524103D0 GB 0524103 D0 GB0524103 D0 GB 0524103D0 GB 0524103 A GB0524103 A GB 0524103A GB 0524103 D0 GB0524103 D0 GB 0524103D0
Authority
GB
United Kingdom
Prior art keywords
healing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0524103.9A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medical Research Council
Original Assignee
Medical Research Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical Research Council filed Critical Medical Research Council
Priority to GBGB0524103.9A priority Critical patent/GB0524103D0/en
Publication of GB0524103D0 publication Critical patent/GB0524103D0/en
Priority to PCT/GB2006/004404 priority patent/WO2007060453A1/en
Priority to JP2008541825A priority patent/JP5383198B2/ja
Priority to EP06820350A priority patent/EP1951259A1/en
Priority to US12/094,322 priority patent/US8273712B2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/44—Medicaments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/001—Use of materials characterised by their function or physical properties
    • A61L24/0015—Medicaments; Biocides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
    • A61L24/10—Polypeptides; Proteins
    • A61L24/106—Fibrin; Fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/22—Lipids, fatty acids, e.g. prostaglandins, oils, fats, waxes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/402—Anaestetics, analgesics, e.g. lidocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
    • A61L2300/406—Antibiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
    • A61L2300/408—Virucides, spermicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents
    • A61L2300/414—Growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/45—Mixtures of two or more drugs, e.g. synergistic mixtures

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Materials Engineering (AREA)
  • Surgery (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
GBGB0524103.9A 2005-11-26 2005-11-26 Healing Ceased GB0524103D0 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
GBGB0524103.9A GB0524103D0 (en) 2005-11-26 2005-11-26 Healing
PCT/GB2006/004404 WO2007060453A1 (en) 2005-11-26 2006-11-24 Promoting wound healing by administering a prostaglandin e and granulocyte-macrophage colony stimulating factor
JP2008541825A JP5383198B2 (ja) 2005-11-26 2006-11-24 プロスタグランジンｅおよび顆粒球マクロファージコロニー刺激因子の投与による創傷治癒の促進
EP06820350A EP1951259A1 (en) 2005-11-26 2006-11-24 Promoting wound healing by administering a prostaglandin e and granulocyte-macrophage colony stimulating factor
US12/094,322 US8273712B2 (en) 2005-11-26 2006-11-24 Promoting wound healing by administering a prostaglandin E and granulocyte-macrophage colony stimulating factor

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0524103.9A GB0524103D0 (en) 2005-11-26 2005-11-26 Healing

Publications (1)

Publication Number Publication Date
GB0524103D0 true GB0524103D0 (en) 2006-01-04

Family

ID=35601276

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0524103.9A Ceased GB0524103D0 (en) 2005-11-26 2005-11-26 Healing

Country Status (5)

Country Link
US (1) US8273712B2 (enExample)
EP (1) EP1951259A1 (enExample)
JP (1) JP5383198B2 (enExample)
GB (1) GB0524103D0 (enExample)
WO (1) WO2007060453A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE532512T1 (de) * 2006-09-14 2011-11-15 Bridge Biores Rights Jersey Ltd Isoniazid-vermittelte heilung von wunden und geschwüren
US20090029868A1 (en) * 2006-10-31 2009-01-29 Applera Corporation Expression signature in peripheral blood for detection of aortic aneurysm
US8455547B2 (en) * 2008-02-05 2013-06-04 Allergan, Inc. Substituted cyclopentanes having prostaglandin activity
CN103153290B (zh) * 2010-10-11 2018-01-16 普渡研究基金会 有助于伤口愈合的抗微生物制剂
CN102488698A (zh) * 2011-12-02 2012-06-13 河南科技大学第一附属医院 一种口腔治疗水
US20140120057A1 (en) * 2012-10-25 2014-05-01 Rutgers, The State University Of New Jersey Polymers and methods thereof for wound healing
JP2017509599A (ja) * 2014-02-05 2017-04-06 レポネックス・ファーマシューティカルズ・エーピーエス 皮膚潰瘍及び創傷の治癒を促進するための組成物
EP3171887A1 (en) * 2014-07-24 2017-05-31 Reponex Pharmaceuticals APS Compositions comprising granulocyte-macrophage colony-stimulating factor for the treatment of inflammatory bowel disease
DE102014014993B4 (de) * 2014-10-09 2017-02-02 Helga Schmetzer Verwendung von immunmodulatorisch wirksamen Kits zur immuntherapeutischen Behandlung von Patienten mit myeloischen Leukämien
CN104490923B (zh) * 2014-12-03 2017-11-17 马广安 愈合膏
CN105919965A (zh) * 2016-04-28 2016-09-07 湖南尔康湘药制药有限公司 一种磺胺脒淀粉胶囊剂及其制备方法
US11904000B2 (en) 2019-05-06 2024-02-20 Brown University Compositions and methods to enhance cutaneous wound healing

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4127612A (en) * 1978-03-17 1978-11-28 Miles Laboratories, Inc. 19-Hydroxy PGE1 carbinol analogues
EP0011471B1 (en) 1978-11-17 1983-02-09 SMITH & NEPHEW RESEARCH LIMITED Adhesive-coated sheet material incorporating anti-bacterial substances
AU594014B2 (en) 1984-03-21 1990-03-01 Research Corporation Technologies, Inc. Recombinant DNA molecules
US5391485A (en) 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
CA2081104A1 (en) * 1991-02-22 1992-08-23 Glenn Pierce Use of gm-csf and g-csf to promote accelerated wound healing
US5662924A (en) 1991-03-21 1997-09-02 Smith & Nephew Plc Wound dressing
CA2107669C (en) * 1992-02-07 2004-06-01 Makoto Okumura Preparation for treating wounds and hemorrhoides
JPH06312941A (ja) * 1992-08-24 1994-11-08 Toshiichi Nakamura Ｈｇｆ産生促進剤
GB9307624D0 (en) * 1993-04-13 1993-06-02 Smith & Nephew Wound dressing
GB9510226D0 (en) * 1995-05-20 1995-07-19 Smith & Nephew Sterilisable cream or paste product for topical application
GB2304047A (en) 1995-08-09 1997-03-12 Univ Manchester Pharmaceutical compositions containing cytokines
GB9701178D0 (en) * 1997-01-21 1997-03-12 Smith & Nephew Dressings
TWI249520B (en) 1998-07-15 2006-02-21 Ono Pharmaceutical Co 5-Thia-omega-substituted phenyl prostaglandin E derivatives, method for producing the same and medicines containing the same as the active ingredient
KR20010074981A (ko) 1998-09-14 2001-08-09 우에노 도시오 ω치환된 페닐프로스타그란딘 Ｅ 유도체 및 그 유도체를유효 성분으로 하는 약제
WO2001008717A1 (en) * 1999-08-03 2001-02-08 Smith & Nephew, Inc. Controlled release implantable devices
EP1221937B1 (en) 1999-10-05 2004-12-15 Transkaryotic Therapies, Inc. Hybrid matrices and hybrid matrix mixtures
AR034262A1 (es) 2000-09-14 2004-02-18 Transkaryotic Therapies Inc Una composicion para proporcionar una mezcla fluida inyectable, un equipo, un metodo para preparacion de una mezcla de dicho equipo, un aparato para la introduccion de una mezcla en un paciente
US20030092163A1 (en) * 2001-07-26 2003-05-15 Collins John Kevin Probiotic bifidobacterium strains
US20040265268A1 (en) * 2001-08-18 2004-12-30 Deepak Jain Compositions and methods for skin rejuvenation and repair
US20030082225A1 (en) 2001-10-19 2003-05-01 Mason Paul Arthur Sterile, breathable patch for treating wound pain
US20040259863A1 (en) * 2001-10-31 2004-12-23 Hans-Michael Eggenweiler Type 4 phosphodiesterase inhibitors and uses thereof
CA2473727A1 (en) * 2001-12-04 2003-06-12 Christopher J. Woolverton Storage-stable fibrin sealant
SE0200667D0 (sv) 2002-03-05 2002-03-05 A & Science Invest Ab Novel use of cytokine inhibitors
AU2003253883A1 (en) 2002-07-15 2004-02-02 The Johns Hopkins University Neuronal and optic nerve gene expression patterns
GB0224415D0 (en) 2002-10-21 2002-11-27 Medical Res Council Compositions
GB0324523D0 (en) 2003-10-21 2003-11-26 Medical Res Council Compositions and methods of treatment
EP1711598A4 (en) 2004-01-30 2009-04-08 Lifecord Inc METHOD OF ISOLATING AND CULTURING MULTIPOTENTED PRECURSOR / STEM CELLS FROM CORDIAL BLOOD BLOOD AND METHOD OF INDUCING THEIR DIFFERENTIATION

Also Published As

Publication number Publication date
JP2009517374A (ja) 2009-04-30
EP1951259A1 (en) 2008-08-06
US20080317705A1 (en) 2008-12-25
WO2007060453A1 (en) 2007-05-31
US8273712B2 (en) 2012-09-25
JP5383198B2 (ja) 2014-01-08

Similar Documents

Publication Publication Date Title
GB0513552D0 (en) Bandage
GB0509613D0 (en) Fixator
ZA200709875B (en) Loincloth diaper
DE502006001600D1 (en) Pyrazolylcarboxanilide
DE602006013270D1 (en) Prrs-impfstoffe
IL187753A0 (en) Wound healing
SI2601972T1 (sl) Terapija ledvičnih kamnov brez litotripsije
DE602006003064D1 (en) Tripeptid- und tetrapeptid-thioether
DE602006009492D1 (en) Fluidmaschinen
DE602006014261D1 (en) Benzimidazolverbindungen
DE602006009835D1 (en) Nthalten
DE502005007477D1 (en) Delta-sigma-modulator
GB0507003D0 (en) Therapeutic
GB0516068D0 (en) Well treatment
GB0511769D0 (en) Treatment
GB0525540D0 (en) New treatment
GB2427141B (en) Fixator
GB0502171D0 (en) Well treatment
DE502006002219D1 (en) Rotationspumpe
DE502006007734D1 (en) Thiazolcarbonsäureanilide
DE502006004337D1 (en) Strangführungsrolle
GB0503644D0 (en) Catstep I
AU3292P (en) DP303 Dianella prunina
AU4036P (en) Dottie Calathea roseo-picta
AU3621P (en) Scacover Scaevola aemula

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)